Clinical Trial Update: Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function [Phase 4]

View source ↗

Summary

Phase 4 trial comparing enoxaparin 20 mg versus 30 mg subcutaneously once daily in elderly patients with renal impairment for venous thromboembolism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Impairment
• Venous Thromboembolism

Drugs mentioned

• Enoxaparin (enoxaparin sodium)

Snippet

Sponsor: Lebanese American University | Conditions: Venous Thromboembolism, Renal Impairment | Phase 4 | Status: COMPLETED